Immunologix holds the exclusive worldwide license rights to a proprietary technique used to produce fully human antibodies. GenScript claimed that it offers antibody drug services that include antigen
Phytomedics is a healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources. PMI-001 is a novel, oral, disease-modifying, botanical drug for
Scynexis, a drug discovery and development company, directs medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial’s animal health discovery efforts. Scynexis president and CEO Yves
As per the terms of the agreement, Biovista will collaborate with Pfizer’s Indications Discovery Unit to identify up to three novel indications for each of the Pfizer candidates.
The collaboration is designed to create new opportunities to further improve the efficacy of several of Merial’s new vaccine development targets. In Cell Art claims that the ICA614
Opexa’s operating loss was $1.29m, compared to $1.21m for the comparable period in 2009. For the nine months ended 30 September 2010, the company has posted a net
The grant was awarded under the Foundation’s Therapeutics Development Initiative aimed at supporting preclinical development of Parkinson’s disease therapies that have the potential for fundamentally altering disease course
PharmFilm is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs, MonoSol Rx said. MonoSol Rx president and CEO Mark
Snowdon is a biopharmaceutical company that specialises in the discovery and development of novel small-molecule therapeutics for the treatment of pain, infectious diseases and nervous system disorders Snowdon
EUSA Pharma submitted its Erwinase BLA on a rolling basis, following receipt of Fast Track designation from the FDA. EUSA Pharma’s completed BLA submission requests Priority Review status,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.